Price (delayed)
$40.72
Market cap
$3.48B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.8
Enterprise value
$3.47B
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that
There are no recent dividends present for CRSP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.